Business
Results of Shareholder Analysis
CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of December 31, 2025, revealing significant holdings by Andrew Webb with 14.10%, Christopher McConville with 9.65%, Brian Murray with 9.49%, David Lawton with 9.28%, and Zeus Dynamic Opportunities Fund with 3.67%. Following recent share issuances, neither Linista Group Inc. nor Spreadex hold a disclosable stake. The company is preparing to initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in glioblastoma patients in Q1 2026. Disclaimer*
About this update from Crism Therapeutics Corporation
[{"type":"text","content":"\n\n09 January 2026\n \n\n \nCRISM Therapeutics Corporation\n(\"CRISM\", \"CRISM Therapeutics\" or the \"Company\")\n \nResults of Shareholder Analysis\nCRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third-party shareholder register analysis, that as at 31 December 2025, the Company is aware of the following significant shareholders, being those with an interest in 3% or more of the ordinary share capital of the Company (\"Ordinary Shares\").\n\n\n\n\nShareholder\n\n\nNo. of Ordinary Shares\n\n\n% interest in the ordinary share capital of the Company\n\n\n\n\nAndrew Webb\n\n\n7,297,190\n\n\n14.10%\n\n\n\n\nChristopher McConville\n\n\n4,992,033\n\n\n9.65%\n\n\n\n\nBrian Murray\n\n\n4,908,700\n\n\n9.49%\n\n\n\n\nDavid Lawton\n\n\n4,802,416\n\n\n9.28%\n\n\n\n\nZeus Dynamic Opportunities Fund\n\n\n1,900,000\n\n\n3.67%\n\n\n\n\nFollowing the issue of the placing and retail offer shares (as announced on 10 and 15 December 2025 respectively) neither Linista Group Inc. or Spreadex hold a disclosable shareholding in the Company.\n-Ends-\n \nEnquiries:\n \n\n\n\n\nCompany\n\n\nNomad and Broker\n\n\nFinancial PR\n\n\n\n\nCRISM Therapeutics Corporation\n\n\nS.P. Angel Corporate Finance LLP\n\n\nBurson Buchanan\n\n\n\n\nAndrew Webb, CEO\nChris McConville, CSO\n\n\nRichard Morrison\nVadim Alexandre\nAdam Cowl\n\n\nMark Court / Jamie Hooper\[email protected]\n\n\n\n\nvia Burson Buchanan\n\n\n+44 (0) 20 3470 0470\n\n\n+44 (0) 20 7466 5000\n\n\n\n\n \n \nAbout CRISM Therapeutics Corporation\n \nCRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.\n \nChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments f...